Klaria Pharma Holding reaches the final subscription deadline for its 147.6 MSEK rights issue, aimed at bolstering liquidity for upcoming commercial milestones and partner-led market entries.
Today, 6 November 2026, is the last subscription day in Klaria's rights issue of units raising up to about MSEK 147.6. This is an administrative reminder of an already-known process rather than new financial information. The raised capital strengthens the balance sheet ahead of partner CNX Therapeutics' planned European launch in Q4 2026, but no new terms, results or surprises are disclosed.
Klaria Pharma Holding AB has confirmed that 6 November 2026 is the final day for shareholders to subscribe to its rights issue of units, aiming to raise approximately 147.6 million SEK. The capital injection is intended to strengthen the company's balance sheet ahead of the planned European product launch by partner CNX Therapeutics in the fourth quarter of 2026.
The rights issue aims to strengthen the company's financial position and liquidity to support commercial operations, including the upcoming European launch of products by partner CNX Therapeutics.